A total of 31 (65%) patients had tumors that were estrogen receptor (ER)- and/or progesterone receptor (PR)-positive and HER2-negative, which aligns with the most common breast cancer subtype globally. The gene discussed is ERBB2; the disease is breast carcinoma.